Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

Withdrawn before enrolling · Phase 1

Conditions studied: Breast Cancer Triple Negative

In brief

The main purpose of this study is to determine how 2 doses mirvetuximab soravtansine affects the amount and activity of folate receptor alpha proteins in tumor cells of patients who have completed standard neoadjuvant treatment and are scheduled to have their tumors surgically removed.

Key facts

Study ID

NCT03045393

Run by

Duke University

People needed

0

Starts

2017-04-17

Expected to finish

2018-02-28

Last updated by the study team

2018-07-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent and HIPAA authorization for release of personal health information.
• Must have operable tumor ≥ 1cm determined by and obtained less than 9 weeks after completion of standard NAC
• Must be able to meet study schedule: 2 doses of mirvetuximab soravtansine administered 3 weeks apart and surgery within 9 weeks of last dose of NAC.
• Willing to undergo biopsy for research purposes only (before and after), and to allow surgical tissue sample from surgery to be used for research purposes
• May have symptoms however must be ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work)
• Demonstrate adequate organ function through labs
• Females of childbearing years must have a negative serum pregnancy test within 48 hours prior to dose 1 mirvetuximab soravtansine. NOTE: Sexually mature females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months
• Females of childbearing potential must be willing to abstain from heterosexual activity or to use two effective methods of contraception from the time of informed consent until 4 months after the last dose of mirvetuximab soravtansine

You may not qualify if…

• Pregnant or breastfeeding, or plan to be pregnant within projected duration of the trial. (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
• Has a known additional malignancy that is active and/or progressive requiring treatment within 3 years of first dose.
• Prior treatment with mirvetuximab soravtansine
• Treatment with any investigational drug within 6 weeks of first clinical dose
• Subjects with > Grade 1 peripheral neuropathy
• Active or chronic corneal disorder, including but not limited to the following:
• Sjogren's syndrome
• Fuchs corneal dystrophy (requiring treatment)
• History of corneal transplantation
• Active herpetic keratitis
• Active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, and acquired monocular vision.
• Serious concurrent illness or clinically-relevant active infection
• Cytomegalovirus infection
• Any concurrent infectious disease, requiring IV antibiotics within 2 weeks of first dose of mirvetuximab soravtansine
• Significant cardiac disease including
• History of neurological conditions that would confound assessment of treatment-emergent neuropathy other than ≤ Grade 1 peripheral neuropathy including multiple sclerosis or other demyelinating disease and/or eaton-lambert syndrome (para-neoplastic syndrome)" Diabetes is allowed.
• History of hemorrhagic or ischemic stroke within 6 months prior to first dose of mirvetuximab soravtansine
• History of cirrhotic liver disease
• Previous clinical diagnosis of non-infectious pneumonitis or non-infectious interstitial lung disease
• Prior hypersensitivity to monoclonal antibodies
• History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to first dose of mirvetuximab soravtansine
• Required used of folate-containing supplements (e.g. for folate deficiency)

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.